TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of General Internal Medicine
Division of Hematology & Oncology
Division of Thoracic Medicine
Division of Infectious Disease
National Taiwan University Hospital Hsin-Chu Branch
(在職)
Division of Thoracic Medicine
Division of General Internal Medicine
National Taiwan University Cancer Center
Division of General Internal Medicine
更新時間：2025-03-04
余忠仁Yu, Chong-Jen
- Principal Investigator
- Clinical Trial Experience (year) 23 years 9 個月
Publication
116Publications
51
Ruan SY, Teng NC, Huang CT, Tsai SL, Wang CY, Wu CP, Hsu JY, Yu CJ, Hsiung C, Wu HD, Chen L. Dynamic Changes in Prognosis with Elapsed Time on Ventilators among Mechanically Ventilated Patients. Ann Am Thorac Soc. 2020 Jun;17(6):729-735. doi: 10.1513/AnnalsATS.201908-646OC. PMID: 32011907; PMCID: PMC7258420.
52
Chang CH, Lee CH, Ko JC, Chang LY, Lee MC, Zhang JF, Wang JY, Shih JY, Yu CJ. Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs. Front Oncol. 2020 Oct 28;10:583529. doi: 10.3389/fonc.2020.583529. PMID: 33194721; PMCID: PMC7656015.
53
Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Su KY, Chang YL, Wu CT, Hsu CC, Liao BC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur J Cancer. 2020 Jan;124:110-122. doi: 10.1016/j.ejca.2019.10.019. Epub 2019 Nov 21. PMID: 31760310.
54
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. PMID: 32955177.
55
Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Liu YN, Su KY, Chang YL, Wu CT, Liao BC, Hsu CC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. Oncologist. 2020 Aug;25(8):702-711. doi: 10.1634/theoncologist.2020-0088. Epub 2020 May 13. PMID: 32386255; PMCID: PMC7418350.
56
Nishio M, Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Cobo M, McKeage M, Su WC, Mok T, Scagliotti GV, Spigel DR, Viraswami-Appanna K, Chen Z, Passos VQ, Shaw AT. Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. J Thorac Oncol. 2020 Apr;15(4):609-617. doi: 10.1016/j.jtho.2019.11.006. Epub 2019 Nov 25. PMID: 31778798.
57
Wang PH, Lin SY, Lee SS, Lin SW, Lee CY, Wei YF, Shu CC, Wang JY, Yu CJ. CD4 response of QuantiFERON-TB Gold Plus for positive consistency of latent tuberculosis infection in patients on dialysis. Sci Rep. 2020 Dec 7;10(1):21367. doi: 10.1038/s41598-020-78374-3. PMID: 33288814; PMCID: PMC7721715.
58
Chen YM, Chih-Hsin Yang J, Su WC, Chong IW, Hsia TC, Lin MC, Chang GC, Chiu CH, Ho CC, Wu SY, Hung JY, Wang CC, Yang TY, Yu CJ. Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan. J Formos Med Assoc. 2020 Dec;119(12):1817-1826. doi: 10.1016/j.jfma.2020.01.004. Epub 2020 Feb 22. PMID: 32094063.
59
Chen CY, Chen KY, Shih JY, Yu CJ. Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer. J Formos Med Assoc. 2020 Oct;119(10):1506-1513. doi: 10.1016/j.jfma.2019.12.007. Epub 2020 Jan 6. PMID: 31917064.
60
Chen LC, Huang HN, Yu CJ, Chien JY, Hsueh PR. Clinical features and treatment outcomes of Mycobacterium chimaera lung disease and antimicrobial susceptibility of the mycobacterial isolates. J Infect. 2020 Apr;80(4):437-443. doi: 10.1016/j.jinf.2020.01.005. Epub 2020 Jan 17. PMID: 31954743.
